# MOG (35-55), human

| | |
|---|---|
| **Cat. No.:** | HY-P2459 |
| **CAS No.:** | 163158-19-8 |
| **Molecular Formula:** | $C_{120}H_{179}N_{35}O_{28}S$ |
| **Molecular Weight:** | 2591.99 |
| **Sequence Shortening:** | MEVGWYRPPFSRVVHLYRNGK |
| **Target:** | Others |
| **Pathway:** | Others |
| **Storage:** | Sealed storage, away from moisture and light, under nitrogen<br>Powder -80°C 2 years<br>-20°C 1 year<br>* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen) |

## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | MOG (35-55), human is a component of CNS myelin. MOG (35-55), human is different from mMOG (35-55) by a proline for serine substitution at position 42. MOG (35-55), human is also immunogenic, but not encephalitogenic, and is only partially cross-reactive with mMOG35–55. MOG (35-55), human induces minimal clinical signs of EAE relative to the rodent peptide[1]. |

## REFERENCES

[1]. Cathleen Rich, et al. Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. Eur J Immunol. 2004 May;34(5):1251-61.

[2]. Alfred R Oliver, et al.Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice. J Immunol. 2003 Jul 1;171(1):462-8.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA